ARGX
argenxยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ARGX Profile
Argenx Se
A global immunology company that develops therapies to treat severe autoimmune diseases and cancer
Biological Technology
04/25/2008
05/18/2017
NASDAQ Stock Exchange
1,599
12-31
Depository Receipts (Ordinary Shares)
Laarderhoogtweg 25, NL-1101 EB Amsterdam, Netherlands
--
Argenx Se was established on 25 April 2008 under the laws of the Netherlands as a private limited liability company (besloten vennootschap met beperkte aansprakelijkheid). On May 28, 2014, the company was converted into a public limited liability company (naamloze vennootschap) under the Notarized Conversion Deed and Amendment. The company is a commercial-stage, global, fully integrated biopharmaceutical company developing differentiated therapies for the treatment of serious autoimmune diseases.
